DTDmitry O. Tsypyshev

Dmitry O. Tsypyshev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dmitry O. Tsypyshev has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacokinetics and Effect of Novel Sydnonimine on NO and cGMP Accumulation In Vivo

    by Nikita S. Popov, Dmitry A. Gavrilenko, Dmitry O. Tsypyshev, Vladimir V. Turovtsev, Mikhail S. Baranov, Dmitry S. Ivanov, Ivan N. Myasnyanko, Diana E. Kaurova, Sergey A. Filatov, Yulia V. Vakhitova, et al.

    Background: Sydnonimines are mesoionic heterocyclic NO donors with vasodilatory activity. Molsidomine, a clinically approved sydnonimine, has limited blood–brain barrier (BBB) penetration, restricting its use for cerebrovascular disorders. This study characterizes the lead compound BBP2023 as a potential NO donor with putative cerebral action. Methods: In silico ADME profiling (RDKit) of 14 sydnonimines, rat pharmacokinetics of oral BBP2023 (11 mg/kg) vs. molsidomine (10.4 mg/kg), HPLC-MS/MS of NO/cGMP, and docking against four human sGC PDB entries were performed. Results: BBP2023 showed high lipophilicity (logP 1.58), low TPSA (69.78 Å2) and predicted high BBB permeability. After oral dosing, BBP2023 was rapidly absorbed (plasma Tmax 0.17 h, Cmax 389 ng/mL, AUC_last 235 h·ng/mL) and extensively distributed, with highest exposure in liver (AUC_last 1457 h·ng/mL, ~6-fold plasma), indicating primary hepatic metabolism. Brain penetration was confirmed (fr = 1.39, MRT 3.01 h). The active metabolite BBP2023 A appeared later (plasma Tmax 1.00 h, Cmax 22 ng/mL) and accumulated in the lungs (fr = 25.31, AUC_last 1569 h·ng/mL) and brain (fr = 3.65, MRT 4.16 h). Compared with molsidomine, BBP2023 achieved higher brain exposure (availability 1.4 vs. 0.2, Cmax 852.5 vs. 142.3 pmol/mL) and faster brain Tmax (≤0.25 h vs. 1 h). BBP2023 significantly increased NO and cGMP in the brain (131.00 ± 26.39 nM/g and 1070.83 ± 92.04 pM/g, respectively), whereas molsidomine predominantly elevated heart NO. Docking and MM-GBSA calculations suggested possible interactions of BBP2023 and its metabolites with the sGC stimulator site and associated the intact sydnonimine ring with more favorable calculated scores. Conclusions: BBP2023 acts as a NO donor with favorable pharmacokinetics, effective BBB penetration, and brain NO/cGMP accumulation, supporting its further development for cerebrovascular disorders.

  • Open Access

    Synthesis and Biological Evaluation of TDP1 Inhibitors Based on Coumarin and Monoterpenoid Fragments Conjoined by Heterocyclic Moieties

    by Dmitriy Tsypyshev, Tatyana Khomenko, Tatyana Kornienko, Alexandra Zakharenko, Nina Komarova, Vyacheslav Krasnov, Natalya Soldatova, Pavel Postnikov, Suat Sari, Konstantin Volcho, et al.

    Tyrosyl-DNA phosphodiesterase 1 (TDP1) represents a compelling pharmacological target for the development of agents designed to circumvent tumor resistance to topoisomerase 1 (TOP1) inhibitors, a major class of clinically relevant antineoplastic drugs. This paper describes the design and synthesis of novel hybrid TDP1 inhibitors combining coumarin and monoterpene moieties via rigid isoxazole and 1,2,3-triazole heterocyclic linkers. The synthesis was accomplished via [3 + 2] cycloaddition of nitrile oxides to alkynes and copper-catalyzed click chemistry. Biological tests have demonstrated the crucial role of linker nature in the activity of the compounds. Isoxazole-linked conjugates showed strong inhibitory effects on TDP1, with IC50 values in the submicromolar to low micromolar range (0.8–3.2 μM). Overall, these values slightly surpassed those of the triazole-linked analogues, whose IC50 values ranged from 1.1 to 23.3 μM. At noncytotoxic doses, compounds 26e and 16b enhanced the sensitivity of human cervical cancer (HeLa) cells to the antitumor agent topotecan, a TOP1 inhibitor, thereby supporting the promise of this structural class as components of combination chemotherapy.

  • Synthesis and cytotoxic activity of 1,5,6,7-tetrahydroindol-4-one derivatives and its thio analogue

    by V. A. Sorokina, D. O. Tsypyshev, A. V. Koval’sKaya, V. A. Vakhitov, I. P. Tsypysheva, Цыпышев Дмитрий Олегович, Ковальская Алёна Витальевна, Вахитов Венер Абсаттарович, Цыпышева Инна Петровна

    Derivatives of 1,5,6,7-tetrahydroindol-4-one and its thio analogue were synthesized and their cytotoxicity against HEK293, Jurkat and MCF-7 cells was investigated in vitro. The hit compound, 6,6-dimethyl-1-(2-methylphenyl)-2-phenyl-1,5,6,7-tetrahydro-4H-indol-4-one, was found to inhibit the metabolic activity of lymphoblastic leukemia cells (Jurkat) with IC50 = 14.8 µM and normal human embryonic kidney cells (HEK293) with IC50 = 93.63 µM. The proposed mechanism of cytotoxic action of the most active compound was shown in silico to be mediated by interaction with the cyclin-dependent kinase CDK9 site.

  • Inhibition of dengue viruses by N-methylcytisine thio derivatives through targeting viral envelope protein and NS2B-NS3 protease

    by Chen-Sheng Lin, Chih-Hao Lu, Tsai-Hsiu Lin, Yan-Tung Kiu, Ju-Ying Kan, Yu-Jen Chang, Ping-Yi Hung, Alena V. Koval'SKaya, Dmitry O. Tsypyshev, Inna P. Tsypysheva, et al.


  • Open Access

    Hybrids of Sterically Hindered Phenols and Diaryl Ureas: Synthesis, Switch from Antioxidant Activity to ROS Generation and Induction of Apoptosis

    by Elmira Gibadullina, Margarita Neganova, Yulia Aleksandrova, Hoang Bao Tran Nguyen, Alexandra Voloshina, Mikhail Khrizanforov, Thi Thu Nguyen, Ekaterina Vinyukova, Konstantin Volcho, Dmitry Tsypyshev, et al.

    The utility of sterically hindered phenols (SHPs) in drug design is based on their chameleonic ability to switch from an antioxidant that can protect healthy tissues to highly cytotoxic species that can target tumor cells. This work explores the biological activity of a family of 45 new hybrid molecules that combine SHPs equipped with an activating phosphonate moiety at the benzylic position with additional urea/thiourea fragments. The target compounds were synthesized by reaction of iso(thio)cyanates with C-arylphosphorylated phenols containing pendant 2,6-diaminopyridine and 1,3-diaminobenzene moieties. The SHP/urea hybrids display cytotoxic activity against a number of tumor lines. Mechanistic studies confirm the paradoxical nature of these substances which combine pronounced antioxidant properties in radical trapping assays with increased reactive oxygen species generation in tumor cells. Moreover, the most cytotoxic compounds inhibited the process of glycolysis in SH-SY5Y cells and caused pronounced dissipation of the mitochondrial membrane of isolated rat liver mitochondria. Molecular docking of the most active compounds identified the activator allosteric center of pyruvate kinase M2 as one of the possible targets. For the most promising compounds, 11b and 17b, this combination of properties results in the ability to induce apoptosis in HuTu 80 cells along the intrinsic mitochondrial pathway. Cyclic voltammetry studies reveal complex redox behavior which can be simplified by addition of a large excess of acid that can protect some of the oxidizable groups by protonations. Interestingly, the re-reduction behavior of the oxidized species shows considerable variations, indicating different degrees of reversibility. Such reversibility (or quasi-reversibility) suggests that the shift of the phenol-quinone equilibrium toward the original phenol at the lower pH may be associated with lower cytotoxicity.


  • Open Access

    Elaboration of the Effective Multi-Target Therapeutic Platform for the Treatment of Alzheimer’s Disease Based on Novel Monoterpene-Derived Hydroxamic Acids

    by Yulia Aleksandrova, Aldar Munkuev, Evgenii Mozhaitsev, Evgenii Suslov, Dmitry Tsypyshev, Kirill Chaprov, Roman Begunov, Konstantin Volcho, Nariman Salakhutdinov, Margarita Neganova

    Novel monoterpene-based hydroxamic acids of two structural types were synthesized for the first time. The first type consisted of compounds with a hydroxamate group directly bound to acyclic, monocyclic and bicyclic monoterpene scaffolds. The second type included hydroxamic acids connected with the monoterpene moiety through aliphatic (hexa/heptamethylene) or aromatic linkers. An in vitro analysis of biological activity demonstrated that some of these molecules had powerful HDAC6 inhibitory activity, with the presence of a linker area in the structure of compounds playing a key role. In particular, it was found that hydroxamic acids containing a hexa- and heptamethylene linker and (-)-perill fragment in the Cap group exhibit excellent inhibitory activity against HDAC6 with IC50 in the submicromolar range from 0.56 ± 0.01 µM to 0.74 ± 0.02 µM. The results of the study of antiradical activity demonstrated the presence of moderate ability for some hydroxamic acids to scavenge 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2ROO• radicals. The correlation coefficient between the DPPH radical scavenging activity and oxygen radical absorbance capacity (ORAC) value was R2 = 0.8400. In addition, compounds with an aromatic linker based on para-substituted cinnamic acids, having a monocyclic para-menthene skeleton as a Cap group, 35a, 38a, 35b and 38b, demonstrated a significant ability to suppress the aggregation of the pathological β-amyloid peptide 1-42. The 35a lead compound with a promising profile of biological activity, discovered in the in vitro experiments, demonstrated neuroprotective effects on in vivo models of Alzheimer’s disease using 5xFAD transgenic mice. Together, the results obtained demonstrate a potential strategy for the use of monoterpene-derived hydroxamic acids for treatment of various aspects of Alzheimer’s disease.


  • Open Access

    Novel Multitarget Hydroxamic Acids with a Natural Origin CAP Group against Alzheimer’s Disease: Synthesis, Docking and Biological Evaluation

    by Margarita Neganova, Yulia Aleksandrova, Evgenii Suslov, Evgenii Mozhaitsev, Aldar Munkuev, Dmitry Tsypyshev, Maria Chicheva, Artem Rogachev, Olga Sukocheva, Konstantin Volcho, et al.

    Hydroxamic acids are one of the most promising and actively studied classes of chemical compounds in medicinal chemistry. In this study, we describe the directed synthesis and effects of HDAC6 inhibitors. Fragments of adamantane and natural terpenes camphane and fenchane, combined with linkers of various nature with an amide group, were used as the CAP groups. Accordingly, 11 original target compounds were developed, synthesized, and exposed to in vitro and in vivo biological evaluations, including in silico methods. In silico studies showed that all synthesized compounds were drug-like and could penetrate through the blood–brain barrier. According to the in vitro testing, hydroxamic acids 15 and 25, which effectively inhibited HDAC6 and exhibited anti-aggregation properties against β-amyloid peptides, were chosen as the most promising substances to study their neuroprotective activities in vivo. All in vivo studies were performed using 5xFAD transgenic mice simulating Alzheimer’s disease. In these animals, the Novel Object Recognition and Morris Water Maze Test showed that the formation of hippocampus-dependent long-term episodic and spatial memory was deteriorated. Hydroxamic acid 15 restored normal memory functions to the level observed in control wild-type animals. Notably, this effect was precisely associated with the ability to restore lost cognitive functions, but not with the effect on motor and exploratory activities or on the level of anxiety in animals. Conclusively, hydroxamic acid 15 containing an adamantane fragment linked by an amide bond to a hydrocarbon linker is a possible potential multitarget agent against Alzheimer’s disease.


  • Open Access

    Involvement of Chaperone Sigma1R in the Anxiolytic Effect of Fabomotizole

    by Mikhail V. Voronin, Yulia V. Vakhitova, Inna P. Tsypysheva, Dmitry O. Tsypyshev, Inna V. Rybina, Rustam D. Kurbanov, Elena V. Abramova, Sergei B. Seredenin

    Sigma-1 receptor (chaperone Sigma1R) is an intracellular protein with chaperone functions, which is expressed in various organs, including the brain. Sigma1R participates in the regulation of physiological mechanisms of anxiety (Su, T. P. et al., 2016) and reactions to emotional stress (Hayashi, T., 2015). In 2006, fabomotizole (ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole dihydrochloride) was registered in Russia as an anxiolytic (Seredenin S. and Voronin M., 2009). The molecular targets of fabomotizole are Sigma1R, NRH: quinone reductase 2 (NQO2), and monoamine oxidase A (MAO-A) (Seredenin S. and Voronin M., 2009). The current study aimed to clarify the dependence of fabomotizole anxiolytic action on its interaction with Sigma1R and perform a docking analysis of fabomotizole interaction with Sigma1R. An elevated plus maze (EPM) test revealed that the anxiolytic-like effect of fabomotizole (2.5 mg/kg i.p.) administered to male BALB/c mice 30 min prior EPM exposition was blocked by Sigma1R antagonists BD-1047 (1.0 mg/kg i.p.) and NE-100 (1.0 mg/kg i.p.) pretreatment. Results of initial in silico study showed that fabomotizole locates in the active center of Sigma1R, reproducing the interactions with the site’s amino acids common for established Sigma1R ligands, with the ΔGbind value closer to that of agonist (+)-pentazocine in the 6DK1 binding site.


  • Thionation of quinolizidine alkaloids and their derivatives via Lawesson’s reagent

    by Alena V. Koval’SKaya, Polina R. Petrova, Dmitry O. Tsypyshev, Alexander N. Lobov, Inna P. Tsypysheva

    Direct thionation of quinolizidine alkaloids (-)-cytisine, methylcytisine, thermopsine and some of their carbonyl derivatives was realized. It was established that carrying out of the reaction in the boiling toluene with 0.5 eq. of Lawesson’s reagent (LR) is most effective for synthesis of thio analogues of methyl-, allyl-, benzylcytisine and thermopsine. It was found, that formation of thioamides is preferable in the case with starting 3-carboxamides of (-)-cytisine or 2-oxo and 4-oxo derivatives of methylcytisine; and an excess of LR is needed for their exhaustive thionation. It was shown, that thionation of ‘cytisine substituted’ urea and thiourea, as well as Diels-Alder adducts of methylcitisine with phenylmaleimide on basis of this approach was not quite successful: only thionation of the 2-pyridone core has occurred. It should be noted that transformation of urea and thiourea is complicated by side reactions leading to low yields of thio products, and the result of LR interaction with mentioned above diastereomeric Diels-Alder adducts depends on their stereochemistry and thermodynamic stability under reaction conditions. Graphical Abstract


  • Diels-Alder adducts of 3-N-substituted derivatives of (−)-Cytisine as influenza A/H1N1 virus inhibitors; stereodifferentiation of antiviral properties and preliminary assessment of action mechanism

    by Inna Tsypysheva, Alena Koval'SKaya, Polina Petrova, Alexander Lobov, Sophia Borisevich, Dmitry Tsypyshev, Victoria Fedorova, Elisaveta Gorbunova, Anastasia Galochkina, Vladimir Zarubaev